A Canadian Working Group Report on Fecal Microbial Therapy: Microbial Ecosystems Therapeutics
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
A working group from across Canada comprised of clinician and basic scientists, epidemiologists, ethicists, Health Canada regulatory authorities and representatives of major funding agencies (Canadian Institutes of Health Research and the Crohn's and Colitis Foundation of Canada) met to review the current experience with fecal microbial therapy and to identify the key areas of study required to move this field forward. The report highlights the promise of fecal microbial therapy and related synthetic stool therapy (together called 'microbial ecosystems therapeutics') for the treatment of Clostridium difficile colitis and, possibly, other disorders. It identifies pressing clinical issues that need to be addressed as well as social, ethical and regulatory barriers to the use of these important therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Health Canada regards FMT as a “New Biologic Drug” and declares that all clinical studies must pass the process of a clinical trial application to ensure it meets quality and safety standards.75”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [75]
In the citing paper
“a YouTube video describing do-it-yourself FMT has been viewed over 45,000 times.112”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · cited 1×
“Information from 16S rRNA sequence analysis can be used to characterize the gross composition of the microbiota using tools such as Quantitative Insights Into Microbial Ecology (31).”
MethodCohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Castellarin, M., Warren, R. L., Freeman, J. D., Dreolini, L., Krzywinski, M., Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R. A., et al. (2012) · Genome Research · doi:10.1101/gr.126516.111 · Cited by 2,043 · cited 1×
“For example, if certain bacterial profiles are associated with colorectal cancer (21,22), their transplantation may have future consequences for the recipient.”
BackgroundSelf-citationDiet Drives Convergence in Gut Microbiome Functions Across Mammalian Phylogeny and Within Humans
Muegge, B. D., Kuczynski, J., Knights, D., Clemente, J. C., González, A., Fontana, L., Henrissat, B., Knight, R., & Gordon, J. I. (2011) · Science · doi:10.1126/science.1198719 · Cited by 1,988 · cited 1×
“In some cases, it has been possible to identify specific groups of organisms that are strongly associated with a particular condition (32).”
BackgroundGenomic analysis identifies association of Fusobacterium with colorectal carcinoma
Kostic, A. D., Gevers, D., Pedamallu, C. S., Michaud, M., Duke, F., Earl, A. M., Ojesina, A. I., Jung, J., Bass, A. J., Tabernero, J., et al. (2012) · Genome Research · doi:10.1101/gr.126573.111 · Cited by 1,960 · cited 1×
“For example, if certain bacterial profiles are associated with colorectal cancer (21,22), their transplantation may have future consequences for the recipient.”
BackgroundLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128 · cited 1×
“Between 2002 and 2005, a large outbreak of the hypervirulent strain NAP1 in Quebec led to quadrupling of annual CDI incidence compared with baseline rates from 1991 (2,3).”
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,020 · cited 1×
“Concern has been expressed that food may be a source of exposure (17), and increases in the prevalence of 078 have been reported internationally (18-20).”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 2×
“Recurrent CDI is believed to result from the inability of the intestinal microbiota to recover and re-establish itself to homeostasis with the host (we henceforth use the term ‘normal’ to mean one that does not cause symptoms and signs of infection), after an initial insult, such as antimicrobial exposure (7-10).”
BackgroundGough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003 · cited 1×
“However, a recent systematic review suggests that administration by NJ tube may be inferior to the rectal route (11).”
Background
Cited by
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731
“The treatment seems equally effective when the young donors are not related [19,23].”
BackgroundSelf-citationOtt, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
“However, Health Canada considers FMT and related synthetic stool therapies as a “New Biologic Drug” and requires any clinical study go through the process of a clinical trial application (CTA) to ensure that quality and safety standards are met.(127) The United States Food and Drug Administration (FDA) has determined…”
Collins, S. M., Kassam, Z., & Bercik, P. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.004 · Cited by 205
Hota, S. S., Sales, V., Tomlinson, G., Salpeter, M. J., McGeer, A., Coburn, B., Guttman, D. S., Low, D. E., & Poutanen, S. M. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw731 · Cited by 192
Self-citationBacteriophages: an underestimated role in human and animal health?
De Paepe, M., Leclerc, M., Tinsley, C. R., & Petit, M.-A. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00039 · Cited by 188
From Stool Transplants to Next-Generation Microbiota Therapeutics
Petrof, E. O., & Khoruts, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.004 · Cited by 186
Self-citationHow the microbiota shapes rheumatic diseases
Van de Wiele, T., Van Praet, J. T., Marzorati, M., Drennan, M. B., & Elewaut, D. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.85 · Cited by 159
The Role of the Microbiome in Rheumatic Diseases
Yeoh, N., Burton, J. P., Suppiah, P., Reid, G., & Stebbings, S. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-012-0314-y · Cited by 155
“difficile infection (CDI) [122, 123] and this remains its main application, with success of over 90 % [124].”
BackgroundMethodInfluentialSelf-citationWang, Z.-K., Yang, Y., Chen, Y., Yuan, J. T., Sun, G., & Peng, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14805 · Cited by 150
The intestinal microbiome in type 1 diabetes
Dunne, J. L., Triplett, E. W., Gevers, D., Xavier, R., Insel, R., Danska, J., & Atkinson, M. A. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12321 · Cited by 126
Microbial ecosystems therapeutics: a new paradigm in medicine?
Petrof, E., Claud, E. C., Gloor, G. B., & Allen‐Vercoe, E. (2012) · Beneficial Microbes · doi:10.3920/bm2012.0039 · Cited by 138
“…revealed that faecal bacteriotherapy treatments of one form or another have been performed in at least 6 major cities in Canada; the attendees at the meeting had collectively performed over 220 faecal bacteriotherapy transplants in total, with cure rates over 90% (Allen-Vercoe et al., 2012).”
BackgroundSelf-citationReactive arthritis: update 2018
Kutzbach, A. G., Chacón-Súchite, J. A., Ferrer, H. R. G., & Iraheta, I. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4022-5 · Cited by 97
Ramai, D., Zakhia, K., Ofosu, A., Ofori, E., & Reddy, M. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0328 · Cited by 113
“thoroughly screened before FMT is performed [42-46].”
Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations
Chu, N. D., Smith, M. B., Perrotta, A. R., Kassam, Z., & Alm, E. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170922 · Cited by 98
Bentaleb, I., Abdelghani, K. B., Rostom, S., Amine, B., Laatar, A., & Bahiri, R. (2020) · Current Clinical Microbiology Reports · doi:10.1007/s40588-020-00152-6 · Cited by 94
Navigating social and ethical challenges of biobanking for human microbiome research
Chuong, K. H., Hwang, D. M., Tullis, D. E., Waters, V. J., Yau, Y. C. W., Guttman, D. S., & O’Doherty, K. C. (2017) · BMC Medical Ethics · doi:10.1186/s12910-016-0160-y · Cited by 86
Self-citationFecal Microbiota Transplantation in Inflammatory Bowel Disease
Boicean, A., Bîrluțiu, V., Ichim, C., Anderco, P., & Bîrsan, S. (2023) · Biomedicines · doi:10.3390/biomedicines11041016 · Cited by 93
Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection
Lapointe-Shaw, L., Tran, K. L., Coyte, P. C., Hancock-Howard, R. L., Powis, J., Poutanen, S. M., & Hota, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149521 · Cited by 66
Self-citationThe Human Microbiome and Public Health: Social and Ethical Considerations
O’Doherty, K. C., Virani, A., & Wilcox, E. (2016) · American Journal of Public Health · doi:10.2105/ajph.2015.302989 · Cited by 68
Self-citationDiagnosis and Management of Clostridium difficile Infection
DuPont, H. L. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.03.016 · Cited by 69
Breast, Milk and Microbes: A Complex Relationship that Does Not End with Lactation
Urbaniak, C., Burton, J. P., & Reid, G. (2012) · Women s Health · doi:10.2217/whe.12.23 · Cited by 66
Self-citationEquine faecal microbiota transplant: Current knowledge, proposed guidelines and future directions
Mullen, K. R., Yasuda, K., Divers, T. J., & Weese, J. S. (2016) · Equine Veterinary Education · doi:10.1111/eve.12559 · Cited by 72
“These guidelines are not strictly evidence-based and optimal practices are unknown (Allen-Vercoe et al. 2012).”
BackgroundSelf-citationType 1 diabetes and gut microbiota: Friend or foe?
Hu, C., Wong, F. S., & Li, W. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.02.006 · Cited by 62
Gut microbiota and obesity: implications for fecal microbiota transplantation therapy
Kang, Y., & Cai, Y. (2017) · HORMONES · doi:10.14310/horm.2002.1742 · Cited by 87
Fecal transplant policy and legislation
Vyas, D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.6 · Cited by 51
Human microbiome restoration and safety
Daliri, E. B., Tango, C. N., Lee, B. H., & Oh, D. (2018) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2018.05.002 · Cited by 53
Fernández, L., Ruíz, L., Jara, J., Orgaz, B., & Rodríguez, J. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02676 · Cited by 57
“In this sense, the concept of minimal or synthetic nichespecific microbial communities can open new therapeutic ways to modify the microbiota of people with different pathologies and overcomes many of the limitations of fecal transfer (Allen-Vercoe et al., 2012; de Vos, 2013).”
BackgroundCanadian Association of Gastroenterology Position Statement: Fecal Microbiota Transplant Therapy
Moayyedi, P., Marshall, J. K., Yuan, Y., & Hunt, R. H. (2014) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2014/346590 · Cited by 44
Tsutsumi, L. S., Owusu, Y., Hurdle, J. G., & Sun, D. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026613666131113154753 · Cited by 42
“After preparation of the donated fecal material, it is delivered into the GI tract via nasogastric tube or rectal retention enema or colonoscopy [122].”
Recurrent Clostridium difficile infection and the microbiome
Almeida, R., Gerbaba, T. K., & Petrof, E. O. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1099-3 · Cited by 38
“While there is no established consensus, many guidance documents have been published [32, 74, 75].”
Self-citationHuman microbiome, infections, and rheumatic disease
Caminer, A. C., Haberman, R. H., & Scher, J. U. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3875-3 · Cited by 37
Kassam, Z., Lee, C., & Hunt, R. H. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.08.007 · Cited by 34
Self-citationImpact of Technical Sources of Variation on the Hand Microbiome Dynamics of Healthcare Workers
Rosenthal, M., Aiello, A. E., Chenoweth, C., Goldberg, D. E., Larson, E., Gloor, G. B., & Foxman, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088999 · Cited by 26
“However, as the reproducibility of the Ion Torrent platform for these types of analyses is excellent provided the number of reads per sample is greater than 1000 [11], this was not a concern.”
BackgroundSelf-citationThe art of targeting gut microbiota for tackling human obesity
Aguirre, M., & Venema, K. (2015) · Genes & Nutrition · doi:10.1007/s12263-015-0472-4 · Cited by 26
“The strains are grown in cultures (defined mixtures that aim to be representative to a native fecal microbiota) and are administered in a suspension to the recipient (Allen-Vercoe et al. 2012; Petrof et al. 2013a).”
BackgroundInfluentialInvasions of Host-Associated Microbiome Networks
Murall, C. L., Abbate, J. L., Touzel, M. P., Allen‐Vercoe, E., Alizon, S., Froissart, R., & McCann, K. S. (2017) · Advances in ecological research/Advances in Ecological Research · doi:10.1016/bs.aecr.2016.11.002 · Cited by 29
Self-citationMedia Discourse on the Social Acceptability of Fecal Transplants
Chuong, K. H., O’Doherty, K. C., & Secko, D. M. (2015) · Qualitative Health Research · doi:10.1177/1049732314568199 · Cited by 24
“In addition, concerns remain about risks to patients from pathogens that are unknown or not typically screened for (Allen-Vercoe et al., 2012).”
BackgroundInfluentialSelf-citationNon-antibiotic therapy forClostridioides difficileinfection: a review
Yang, J., & Yang, H. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1648377 · Cited by 28
Munoz, S., Guzmán-Rodríguez, M., Sun, J., Zhang, Y., Noordhof, C., He, S.-M., Allen‐Vercoe, E., Claud, E. C., & Petrof, E. O. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1188248 · Cited by 21
Self-citationEdelstein, C. A., Kassam, Z., Daw, J. R., Smith, M. B., & Kelly, C. R. (2015) · Clinical Research and Regulatory Affairs · doi:10.3109/10601333.2015.1046602 · Cited by 24
“The application to conduct a clinical trial is relatively extensive and requires a risk-benefit assessment by Health Canada, which includes an on-site evaluation and submission of information to confirm the consistency of the potency and purity of the product being tested (many of which are illdefined in the context o…”
BackgroundInfluentialA Practical Method for Preparation of Fecal Microbiota Transplantation
Perez, E., Lee, C., & Petrof, E. O. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6361-4_19 · Cited by 21
Self-citationNavigating Long-Term Safety in Fecal Microbiota Transplantation
Kassam, Z., Lee, C., Yuan, Y., & Hunt, R. H. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.214 · Cited by 18
Self-citationIshida, R. K., Faintuch, J., Safatle‐Ribeiro, A. V., Ribeiro, U., & Cecconello, I. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1277-z · Cited by 17
Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome
Wang, Y., Zheng, F., Liu, S., & Luo, H. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/9759138 · Cited by 18
Allen‐Vercoe, E., & Petrof, E. O. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.13.16 · Cited by 17
Self-citationIf microbial ecosystem therapy can change your life, what's the problem?
Ettinger, G., Burton, J. P., & Reid, G. (2013) · BioEssays · doi:10.1002/bies.201300015 · Cited by 11
Self-citationDowle, C. (2016) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzw007 · Cited by 16
Bourlioux, P. (2013) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2013.02.005 · Cited by 14
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · BMC Veterinary Research · doi:10.1186/s12917-024-04166-w · Cited by 8
The microbiome: what it means for medicine
Allen‐Vercoe, E., & Petrof, E. O. (2014) · British Journal of General Practice · doi:10.3399/bjgp14x677374 · Cited by 4
Self-citationUsing bugs as drugs: Microbial ecosystem therapeutics
Allen‐Vercoe, E., & Petrof, E. (2015) · Canada Communicable Disease Report · doi:10.14745/ccdr.v41is5a01 · Cited by 3
Self-citationRussian experience in fecal microbiota transplantation
Vlassov, V. V., & Morozov, V. V. (2023) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-212-4-113-120 · Cited by 3
Treating recurrent C. difficile infection—the challenge continues
Surawicz, C. M. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.240 · Cited by 3
FMT Regulatory Challenges and the Lived Experiences of People With IBD
Haw, J., Chuong, K. H., & O’Doherty, K. C. (2017) · The American Journal of Bioethics · doi:10.1080/15265161.2017.1299253 · Cited by 3
“…treatment in a number of health conditions, most notably Clostridium difficile infections (CDI) and potentially other gastrointestinal disorders (Allen-Vercoe et al. 2012; Aroniadis and Brandt 2013), there is increasing need to address regulatory challenges and their associated ethical and…”
BackgroundInfluentialSelf-citationThe modulatory approaches of microbiome therapeutics
Tembhre, M. K., Shipra, Imran, S., & Jaiswal, K. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00013-6 · Cited by 4
Navigating the Pediatric Microbiome: Emerging Evidence and Clinical Implications
Kassam, Z., & Murray, T. S. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0040-1 · Cited by 2
“Although there are various donor selection criteria reported [67, 68], there are noteworthy omissions regarding obesity and neuro-psychiatric metrics.”
Inflammatory Bowel Diseases: What Do We Still Need to Investigate?
Taus, M., Busni, D., Fumelli, D., Paci, A., Nicolai, G., & Nicolai, A. (2015) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2015.510024 · Cited by 1
FMT Happens: Regulating Fecal Microbiota Therapy in Canada; What You Need to Know
Salman, S., Vardatsikos, G., Avard, D. M., Palmour, N., Dewar, K., & Zawati, M. H. (2016) · World Medical & Health Policy · doi:10.1002/wmh3.174 · Cited by 1
Reid, G. (2013) · Springer eBooks · doi:10.1007/978-3-642-30144-5_89 · Cited by 1
Self-citationHow probiotics and the microbiome will change medical practice
Reid, G. (2015) · Scholarship@Western (Western University)
Self-citationThe Human Microbiome Project: Beginning and Future Status
Murray, P. R. (2013) · Annals of Clinical Microbiology · doi:10.5145/acm.2013.16.4.162 · Cited by 1
“For example, patients with chronic relapsing CDIs have been successfully treated with stool transplants from a spouse or close relative, as well as with artificially created stool specimens consisting of a complex mixture of aerobic and anaerobic fecal organisms [18,19].”
BackgroundSeeing a Difference in C. diff
Tappenden, K. A. (2012) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607112464856
The gut microbiota and childhood weight development
Mbakwa, C. A. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161006cm
The Future of Gut Microbiota and Nutrition
Ishiguro, E. E., Haskey, N., & Campbell, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-810541-2.00010-5
Recours à des bactéries en tant que médicaments : traitements de l’écosystème microbien
Allen‐Vercoe, E., & Petrof, E. (2015) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v41is5a01f
Self-citationLong, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747492
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747486
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747510
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26241298
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747507
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747501
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747513
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747498
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747489
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747495
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747504
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26241184
Metadata
- Authors
- Allen-Vercoe, E., Reid, G., Viner, N., Gloor, G. B., Hota, S., Kim, P., Lee, C., O’Doherty, K. C., Vanner, S. J., Weese, J. S., & Petrof, E. O.
- Affiliations
- University of Guelph, Guelph, Canada
- Western University (CA)
- Health Canada (CA)
- University of Toronto (CA)
- University of Guelph (CA)
- McMaster University (CA)
- Queen's University (CA)
- Corresponding author
- Petrof, Elaine O
- Venue
- Canadian Journal of Gastroenterology
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 26
- Issue
- 7
- Pages
- 457-462
- ISSN
- 0835-7900 (ISSN-L)
- PMC
- PMC3395448
- OpenAlex
- W41667184
- Cited by
- 81
- References
- 39
- Citations by year
- 2024: 12 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 6 · 2017: 7 · 2016: 11 · 2015: 11 · 2014: 11 · 2013: 11 · 2012: 4
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Canadian Journal of Gastroenterology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Infectious Diseases Society of America
- Canadian Institutes of Health Research (94314)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- fecal microbiota transplantation, Clostridium difficile infection, gut microbiota, regulatory challenges, ethical considerations, clinical research priorities, inflammatory bowel disease
- MeSH terms
- Canada, Congresses as Topic, Enterocolitis, Pseudomembranous, Feces, Gastroenterology, Humans, Ecosystem, Computational Biology, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.